Background: Isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Mutations of Arg-132 in IDH to Cys, His, Leu or Ser abolish magnesium binding and the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R-2-hydroxyglutarate. Elevated levels of R-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.
Immunogen: A synthetic peptide from the internal region of IDH2 which includes the mutation of R140Q, human origin.
Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 50% glycerol
Species Reactivity: Recognizes R140Q mutant, but not wild type IDH2 of vertebrates.
Storage Conditions: Store at -20°C. Avoid repeated freezing and thawing
Western blot:
Western blot analysis of recombinant IDH2(R140Q) and wild type proteins.
Purified His-tagged IDH2(R140Q) protein (lane 2) and corresponding wild type protein (lane 1) were blotted with anti IDH2(R140Q) monoclonal antibody (Cat. #TD-26165).
Immunofluorescence:
Immunofluorescence of cells expressing IDH2 proteins with anti IDH2(R140Q) antibody.
HEK293T cells were transfected with pCDNA3-GFP-IDH2 (WT) plasmid (left column) or pCDNA3-GFP-IDH2(R140Q) plasmid (right column), then fixed and stained with anti-IDH2(R140Q) monoclonal antibody (Cat. #TD-26165).